์ํฐ๋๋ก ์ฐ ์ด๋ํธ๋ฅจ
**์ํฐ๋๋ก ์ฐ ์ด๋ํธ๋ฅจ(Etidronate disodium)**์ 1์ธ๋ **๋น์คํฌ์คํฌ๋ค์ดํธ** ์ฝ๋ฌผ๋ก, ์์ํ์์๋ ์ฃผ๋ก ์ฌ๊ฐํ **์ ์ฑ ์ข ์ ์ฐ๊ด ๊ณ ์นผ์ํ์ฆ**์ ๊ด๋ฆฌํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. * ์ ์ ๋ฐ ๋น์ ์์ ์ธ ๊ณจํก์๋ฅผ ๊ฐ๋ ฅํ๊ฒ ์ต์ ํฉ๋๋ค. * ์ญ์ฌ์ ์ผ๋ก ์ค์ํ ์ฝ๋ฌผ์ด์ง๋ง, ํ์ฌ๋ ํฌ์ฌ ๋น๋๊ฐ ์ ๊ณ ์์ ์ฑ์ด ๋ ๋ฐ์ด๋ ์๋ก์ด ์ง์ ํจ์ ๋น์คํฌ์คํฌ๋ค์ดํธ(์: ํ๋ฏธ๋๋ก ์ฐ, ์กธ๋ ๋๋ก ์ฐ)๋ก ๋์ฒด๋๋ ์ถ์ธ์ ๋๋ค. * **์์ ์์ **: ์ํฐ๋๋ก ์ฐ๊ณผ ๊ฐ์ 1์ธ๋ ๋น์คํฌ์คํฌ๋ค์ดํธ๋ฅผ ์ฅ๊ธฐ ์ฌ์ฉํ๋ฉด ๊ณจ ๋ฌด๊ธฐ์งํ๊ฐ ์์๋ ์ ์์ผ๋ฉฐ, ์๋ก์ด ์ธ๋์ ์ฝ๋ฌผ์์๋ ์ด๋ฌํ ์ํ์ด ํฌ๊ฒ ๊ฐ์ํ์ต๋๋ค.
์์ฉ ๊ธฐ์ : Etidronate is a non-nitrogenous bisphosphonate that acts as a non-hydrolyzable analog of **pyrophosphate**. * Binds strongly to **hydroxyapatite crystals** in the bone matrix. * During bone resorption, the drug is taken up by **osteoclasts**. * Intracellularly, it is incorporated into non-hydrolyzable, cytotoxic ATP analogs โ inhibits ATP-dependent intracellular enzymes โ induces **osteoclast apoptosis**. * Decreased osteoclast activity โ reduced bone resorption โ lowered serum calcium levels. * Additionally increases serum phosphate, presumably by enhancing renal tubular reabsorption.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- For severe hypercalcemia associated with neoplastic disease ยท 5-20 mg/kg/day PO ยท PO ยท q24h
- For severe hypercalcemia associated with neoplastic disease ยท 5-15 mg/kg daily to twice daily PO ยท PO ยท q12-24h ยท for moderate to severe hypercalcemia
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Severe renal function impairment (serum creatinine >5 mg/dL)
์ด์๋ฐ์
- Diarrhea
- Nausea (with higher oral doses)
- Bone pain/tenderness
- Increases in serum creatinine
- 'Frozen bone' syndrome in dogs (weakened bones and fractures due to inhibited bone remodeling)
์ฝ๋ฌผ ์ํธ์์ฉ
- Antacids, dairy products, mineral supplements (iron, magnesium, calcium, aluminum) ยท Absorption of oral etidronate may be inhibited; separate etidronate doses from these substances by at least two hours.
๋ชจ๋ํฐ๋ง
- Serum calcium
- Serum protein
๊ณผ์ฉ๋
Overdoses may result in **hypocalcemia** (ECG changes may occur), **bleeding problems** (secondary to rapid chelation of calcium), and **proximal renal tubule damage**. * **Treatment**: Use standard gut emptying protocols after oral ingestion when warranted. * IV calcium administration (e.g., calcium gluconate) may be used to reverse hypocalcemia. * Intensive monitoring is suggested.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.